Benefit from Superb Weight Loss Results Pointers
“I have a list of medications that I take,” Gale told ABC30. Patients like Gale might not need meds at all. Doctors at Washington University are studying the EndoBarrier for type2 diabetes. “It’s essentially doing the same kind of thing that you would get from surgery,” Shelby Sullivan, MD, Gastroenterologist, Washington University in St. Louis, told ABC30. Doctors insert the plastic-like device through a tube, passed through the mouth and stomach into the first part of the small intestines. When food passes, the EndoBarrier forms a barrier between it and digestive enzymes in the intestine. Researchers believe the device may also alter hormone signals in the digestive tract. “It’s affecting metabolism in a way that it’s improving diabetes,” Dr. Sullivan said. The device is already approved in Europe, Australia, Chile, and Israel, but is still in clinical trials in the U.S. In previous studies, patients experienced a weight loss of about 20 percent and improved their hemoglobin A1c levels by two points. “That helps a diabetic because it’s getting their blood sugar under control. So, it actually may help them get off medication,” Dr.
Done with diabetes: No meds, no surgery
this week revealed that its new Fuse system improves the accuracy of colonoscopies and reduces the number of adenomas missed during surgery, according to research released by EndoChoice. The Fuse system has now been approved for commercial sale in Australia. According to business development manager, Chris Vat, Fuse is the first major breakthrough in endoscopy imaging for many years and the early demand from Australian & New Zealand based gastroenterologists certainly reflects that. We are excited to be launching a product which has such immense potential to improve patient clinical health outcomes in the short term. EndoChoice’s Fuse system is a proprietary arrangement of three small cameras at the tip of a flexible endoscope. By using three cameras, the Fuse system allows doctors to see nearly twice as much surface area as they can with traditional endoscopes that only use one camera. Because of the folds that occur naturally in the colon and stomach anatomy, problem areas can easily go undetected when using traditional endoscopes. The Fuse system allows doctors to see into and behind those folds, effectively looking backwards as well as the traditional forward view. In a multi-center trial conducted in the United States, Europe and Israel, Professor Ian Gralnek and a team of researchers performed a series of colonoscopies comparing traditional endoscopes and the new Fuse system. The endoscope used in the first examination was selected randomly. After the first inspection, each patient immediately underwent a second colonoscopy performed by the same doctor, but with the competing endoscope. The 185 patient trial showed traditional colonoscopes missed 42 percent of adenomas, while the Fuse system missed just 8 percent. After 28 adenomas were found using traditional endoscopes another 20 were found by Fuse for an incremental find rate of 71 percent. “Traditional endoscopes provide up to 170 degrees of forward vision. The advantage of Fuse is that it allows endoscopists to examine twice the anatomy with a wide 330 degree view,” said Ian Gralnek, MD, MSHS, FASGE, Rappaport Faculty of Medicine, Technion -Israel Institute of Technology and Department of Gastroenterology, Rambam Health Care Campus. “Our findings are compelling and support the data from previous studies showing the limitations of traditional endoscopes.
Optiscan Imaging (ASX: OIL) has noted commencement of a clinical study that is introducing Optiscan’s second generation endomicroscopy platform into the field of gastroenterology. The study is being undertaken by gastroenterologists and scientists from the Garvan Institute of Medical research and St Vincent’s Hospital in Sydney, in affiliation with the University of New South Wales. The gastroenterology market is now well established as a result of extensive use of Optiscan’s previous generation platform via a product marketed by Pentax Medical Corporation. The study has enabled the incorporation of the latest advances in Optiscan’s technology into a high definition Olympus endoscope. The resultant system combines advanced features of the Olympus endoscope with Optiscan’s latest developments in microscopic imaging during endoscopy. The result is an endoscope with a level of performance never before trialled in humans, incorporating desirable features discovered using the first generation product during thousands of endoscopy procedures, and other advances in endoscopic imaging. This study will apply these novel features in dynamic events relating to the permeability, or “leakiness” of the gut lining and how it is altered by inflammatory diseases. For Optiscan, the commencement of patient recruitment in this study is a key milestone in its strategy to advance the second generation platform into commercially viable markets. The same platform is currently the subject of product development for neurosurgery under a commercial partnership with Carl Zeiss of Germany, as well as a supply agreement recently secured with UK based MR Solutions for global supply into the pre-clinical imaging market. Optiscan is capitalised at around $10 million. Proactive http://en.wikipedia.org/wiki/Cognitive_behavioral_analysis_system_of_psychotherapy Investors Australia is the market leader in producing news, articles and research reports on ASX Small and Mid-cap stocks with distribution in Australia, UK, North America and Hong Kong / China. Sign up to Proactive Investors Andrew McCrea’s Research Reports Sign up to Andrew McCrea’s Research Reports and Receive Latest Research & Flash Trades Submit Receive Proactive Investors Newsletter, Investor Forum Invites Receive Proactive Investors Newsletter, Event Invites, Special Stock Notifications Submit
Optiscan Imaging’s endomicroscope being used in clinical gastroenterology study